

No: 13.../TKKT

Ho Chi Minh City, April 21, 2025

To: - State Securities Commission of Vietnam
- Hanoi Stock Exchange

Subject: *Explanation of the Consolidated Business Results for Q1 2025 with a Difference of More Than 10% Compared to the Same Period in 2024*

Pursuant to Circular No. 96/2020/TT-BTC guiding information disclosure on the securities market, Mekophar Chemical Pharmaceutical Joint Stock Company (Stock Code: MKP) hereby explains the Consolidated business performance in the first quarter of 2025, which differs by more than 10% compared to the first quarter of 2024 as follows:

Performance Results of Q1 2025 Compared to Q1 2024 – Consolidated Financial Statements:

Indicator	Q1 2025	Q1 2024	Difference	(%)
Revenue	229,738,895,538	245,310,900,436	- 15,572,004,898	-6.3%
Cost of Goods Sold	176,387,497,712	166,637,731,820	9,749,765,892	5.9%
Selling Expenses	30,982,842,786	26,164,468,622	4,818,374,164	18.4%
Administrative Expenses	36,993,709,294	33,800,860,616	3,192,848,678	9.4%
Net Profit After Tax	- 13,452,585,160	14,219,702,486	- 27,672,287,646	-194.6%

Reason: Net profit after tax in the first quarter of 2025 decreased by 194.6% mainly due to a decline in revenue, while selling expenses and general & administrative expenses rose significantly as a result of increased input prices.

This information has been published on the Company's website at: <https://mekophar.com/> in the "Investor Relations" section.

The Company affirms that the information provided is accurate and takes full responsibility for the disclosed content.

Recipient:

- As above
- Archive

GENERAL DIRECTOR



Pharm. Huỳnh Thị Lan